Evidence map›Paper›PMID 31969643›Full record

ArticleScientific reports2020

Tannic acid inhibits lipid metabolism and induce ROS in prostate cancer cells.

Prashanth K B Nagesh, Pallabita Chowdhury, Elham Hatami, Shashi Jain, Nirnoy Dan, Vivek Kumar Kashyap, Subhash C Chauhan, Meena Jaggi, Murali M Yallapu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Food & nutrition research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Prashanth K B NageshDepartment of Microbiology and Immunology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, 78504, USA.
Pallabita ChowdhuryDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Elham HatamiDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Shashi JainTumor Initiation and Maintenance, Sanford-Burnham Medical Research Institute, La Jolla, California, 92037, USA.
Nirnoy DanDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Vivek Kumar KashyapDepartment of Microbiology and Immunology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, 78504, USA.
Subhash C ChauhanDepartment of Microbiology and Immunology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, 78504, USA.
Meena JaggiDepartment of Microbiology and Immunology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, 78504, USA.
Murali M YallapuDepartment of Microbiology and Immunology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, 78504, USA. murali.yallapu@utrgv.edu.
Center for Cancer Research · USUniversity of Tennessee Health Science Center · USThe University of Texas Rio Grande Valley · USUniversity of California, San Diego · US

Funding

MUC13 Mucin in Colorectal Cancer Health DisparityR01CA204552 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2020
$1.7M
Development of Targeted Nanotechnology Platform for Pancreatic CancerR01CA206069 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
Targeted Nanotherapy for Pancreatic CancerR01CA210192 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
PSMA Targeted Docetaxel Loaded Magnetic Nanoparticles for Prostate Cancer TherapyK22CA174841 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI YALLAPU, MURALI MOHAN · 2015 to 2017
$485k
NCI NIH HHS K22 CA174841NCI NIH HHS R01 CA204552NCI NIH HHS R01 CA206069NCI NIH HHS R01 CA210192
6 · The paper itself

Abstract

Prostate cancer (PCa) cells exploit the aberrant lipid signaling and metabolism as their survival advantage. Also, intracellular storage lipids act as fuel for the PCa proliferation. However, few studies were available that addressed the topic of targeting lipid metabolism in PCa. Here, we assessed the tannic acid (TA) lipid-targeting ability and its capability to induce endoplasmic reticulum (ER) stress by reactive oxygen species (ROS) in PCa cells. TA exhibited dual effects by inhibiting lipogenic signaling and suppression of lipid metabolic pathways. The expression of proteins responsible for lipogenesis was down regulated. The membrane permeability and functionality of PCa were severely affected and caused nuclear disorganization during drug exposure. Finally, these consolidated events shifted the cell's survival balance towards apoptosis. These results suggest that TA distinctly interferes with the lipid signaling and metabolism of PCa cells.

Indexed as

ApoptosisCell Line, TumorCell ProliferationCell SurvivalEndoplasmic Reticulum StressHumansLipid MetabolismMaleProstateProstatic NeoplasmsReactive Oxygen SpeciesSignal TransductionTanninsReactive Oxygen SpeciesTannins

Identifiers

PMID31969643
PMCPMC6976712
OpenAlexW3000953621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.